🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07477600
Starting soon Phase 1/2

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600 · tracked via the Priya Life Science China tracker
Sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1/2
Started
2027-06-30
Last updated
2026-08-27

Condition(s) studied

Chronic Obstructive Pulmonary Disease (COPD)

Investigational drug(s) / intervention(s)

clonal fetal MSCs

clonal fetal MSCs: cfMSCs to treat Chronic Obstructive Pulmonary Disease

Study summary

The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Ability to understand the study protocol and the willingness to provide written informed consent; 2. Age 40-80 years old, male or female; 3. Diagnosed with moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD Ⅱ-Ⅳ). 4. Regular use of COPD conventional drugs for more than 3 months, and the condition is stable for more than 4 weeks; 5. ineffective clinical treatment; 6. Life expectancy \> 6 months; 7. At least six months smoking cessation, including non-smoking during the treatment and follow-up periods of the study. Exclusion Criteria: 1. Combined with other serious lung diseases: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, pulmonary hypertension, etc.; 2. A history of lung surgery (pneumonectomy, lung volume reduction surgery, etc.) or bronchial intervention surgery within 12 months; 3. Invasive or non-invasive mechanical ventilation history within 4 weeks, or moderate to severe acute exacerbation of COPD within 4 weeks; 4. Negative for HIV, HCV or syphilis serology; 5. A history of malignant tumors or malignant tumors under treatment; 6. Autoimmune diseases requiring long-term use of glucocorticoids or immunosuppressants; 7. Poorly controlled diabetes (fasting blood glucose \> 10.0 mmol/L) or severe metabolic diseases; 8. A history of alcohol or drug abuse, or mental diseases that cannot cooperate with the study; 9. Pregnancy or breastfeeding. 10. Unable or unwilling to comply with study specific schedules or procedures.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shenzhen Geno-immune Medical Institute Shenzhen Guangdong

More Shenzhen Geno-Immune Medical Institute trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07477600 on ClinicalTrials.gov ↗ ← All trials in China